Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment

Tervonen, Tommi; Fox, Robert J.; Brooks, Anne M. V.; Sidorenko, Tatiana; Boyanova, Neli; Levitan, Bennett; Hennessy, Bryan T.; Phillips-Beyer, Andrea

doi:10.1177/20552173221150370

Cited by 4 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This analysis used data from a web-based DCE that assessed treatment preferences of adults with active RMS, including clinically isolated syndrome (CIS), RRMS, or active SPMS (currently under review at Multiple Sclerosis Journal—Experimental, Translational and Clinical ). 12 The DCE was conducted in the United States, United Kingdom, Poland, and Russia. Here, we describe additional analyses based on that DCE.…”

Section: Methodsmentioning

confidence: 99%

“…The current study aimed to understand the clinical relevance of the difference in fatigue scores between ponesimod and teriflunomide in the OPTIMUM trial. This was achieved by combining data from OPTIMUM and from a recent DCE 12 to determine the number of relapses per year and the change in time to MS progression that patients regarded as equal in importance as the treatment difference in fatigue observed in OPTIMUM. This equivalent relapse rate was contextualized by comparing it to the treatment difference in OPTIMUM.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial

Fox

Tervonen²,

Phillips-Beyer³

et al. 2022

Mult Scler

View full text Add to dashboard Cite

Background: In the OPTIMUM trial in patients with relapsing MS, treatment differences in annualized relapse rate (ARR, 0.088) and change in fatigue at week 108 (3.57 points, measured using the Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple Sclerosis, symptom domain (FSIQ-RMS-S)) favored ponesimod over teriflunomide. However, the importance of the fatigue outcome to patients was unclear. Objective: To assess the importance of the OPTIMUM FSIQ-RMS-S results using data from an MS discrete choice experiment (DCE). Methods: The DCE included components to correlate levels of physical and cognitive fatigue with FSIQ-RMS-S scores. Changes in relapses/year and time to MS progression equivalent to the treatment difference in fatigue in OPTIMUM were determined for similar fatigue levels as mean baseline fatigue in OPTIMUM. Results: DCE participants would accept 0.06 more relapses/year or a 0.15–0.17 year decrease in time to MS progression for a 3.57-point difference in physical fatigue on the FSIQ-RMS-S. To improve cognitive fatigue by 3.57-points on the FSIQ-RMS-S, DCE participants would accept 0.09–0.10 more relapses/year or a 0.24–0.28 year decrease in time to MS progression. Conclusion: MS patients would accept 0.06 more relapses/year to change their fatigue by a similar magnitude as the between-treatment difference observed in the OPTIMUM trial.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial

Fox

Tervonen²,

Phillips-Beyer³

et al. 2022

Mult Scler

View full text Add to dashboard Cite

show abstract

“…Tervonen et al observed how they are more willing to endure an increased rate of relapses and accelerated progression in exchange for alleviating cognitive and physical fatigue. This was especially true when considering the ones who had received their diagnosis more than a decade before (Tervonen et al, 2023).…”

Section: Impact Of Fatigue On Quality Of Lifementioning

confidence: 99%

Fatigue: Physiology and Pathology

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

Section: Current State-of-the-art In Fatigue In Msmentioning

confidence: 99%

Management of multiple sclerosis fatigue in the digital age: from assessment to treatment

Pinarello,

Elmers,

Inojosa

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

Fatigue is one of the most disabling symptoms of Multiple Sclerosis (MS), affecting more than 80% of patients over the disease course. Nevertheless, it has a multi-faceted and complex nature, making its diagnosis, evaluation, and treatment extremely challenging in clinical practice. In the last years, digital supporting tools have emerged to support the care of people with MS. These include not only smartphone or table-based apps, but also wearable devices or novel techniques such as virtual reality. Furthermore, an additional effective and cost-efficient tool for the therapeutic management of people with fatigue is becoming increasingly available. Virtual reality and e-Health are viable and modern tools to both assess and treat fatigue, with a variety of applications and adaptability to patient needs and disability levels. Most importantly, they can be employed in the patient's home setting and can not only bridge clinic visits but also be complementary to the monitoring and treatment means for those MS patients who live far away from healthcare structures. In this narrative review, we discuss the current knowledge and future perspectives in the digital management of fatigue in MS. These may also serve as sources for research of novel digital biomarkers in the identification of disease activity and progression.

show abstract

Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment

Cited by 4 publications

References 34 publications

The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial

The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial

Fatigue: Physiology and Pathology

Management of multiple sclerosis fatigue in the digital age: from assessment to treatment

Contact Info

Product

Resources

About